EQS-Adhoc: SCHOTT Pharma AG & Co. KGaA: SCHOTT Pharma publishes preliminary Q3 key figures and raises 2026 revenue and earnings guidance
|
EQS-Ad-hoc: SCHOTT Pharma AG & Co. KGaA / Key word(s): Forecast / Full year/Results / Quarter
Based on preliminary figures for the third quarter of 2026, SCHOTT Pharma expects constant-currency revenue growth of approximately 8% and an EBITDA margin of approximately 27%. Current market expectations are for constant-currency revenue growth of 3.5% and an EBITDA margin of 27.5% (Source: Vara Consensus, July 6, 2026).
For fiscal year 2026, SCHOTT Pharma now expects constant-currency revenue growth of 5% to 6% (previously: 2% to 5%) and an EBITDA margin of 27% to 28% (previously: around 27%). Both figures are above current market expectations of 3.2% for constant-currency revenue growth and 27.2% for the EBITDA margin (Source: Vara Consensus, July 6, 2026). The raised guidance is supported by the company’s strong business performance and expectations for the fourth quarter of 2026, as well as an agreement reached with a key customer for glass syringes. This agreement includes both revenue-related and compensation components, which will have an impact on future periods. SCHOTT Pharma will publish its Q3 2026 quarterly statement on August 12, 2026. Notifying person: Tobias Erfurth Head of Investor Relations SCHOTT Pharma AG & Co. KGaA Hattenbergstr. 10, 55122 Mainz, Germany phone: +49 (0)6131 661640 Tobias.Erfurth@schott.com www.schott-pharma.com End of Inside Information
08-Jul-2026 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | SCHOTT Pharma AG & Co. KGaA |
| Hattenbergstraße 10 | |
| 55122 Mainz | |
| Germany | |
| Phone: | +49 6131660 |
| E-mail: | ir.pharma@schott.com |
| Internet: | https://ir.schott-pharma.com/ |
| ISIN: | DE000A3ENQ51 |
| WKN: | A3ENQ5 |
| Indices: | SDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate BSX |
| EQS News ID: | 2362904 |
| End of Announcement | EQS News Service |
|
|
2362904 08-Jul-2026 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | ||
| Sales1 | 584,23 | 648,67 | 821,14 | 898,60 | 957,09 | 986,21 | 1.040,00 | |
| EBITDA1,2 | 131,94 | 164,10 | 219,73 | 239,00 | 257,55 | 280,26 | 286,00 | |
| EBITDA-Margin3 | 22,58 | 25,30 | 26,76 | 26,60 | 26,91 | 28,42 | 27,50 | |
| EBIT1,4 | 98,22 | 127,66 | 164,38 | 192,38 | 192,58 | 200,82 | 209,00 | |
| EBIT-Margin5 | 16,81 | 19,68 | 20,02 | 21,41 | 20,12 | 20,36 | 20,10 | |
| Net Profit (Loss)1 | 77,63 | 101,17 | 125,85 | 151,93 | 150,35 | 146,98 | 152,00 | |
| Net-Margin6 | 13,29 | 15,60 | 15,33 | 16,91 | 15,71 | 14,90 | 14,62 | |
| Cashflow1,7 | 104,40 | 132,21 | 182,12 | 181,65 | 225,33 | 179,92 | 184,00 | |
| Earnings per share8 | 0,51 | 0,67 | 0,83 | 1,01 | 0,99 | 0,97 | 1,00 | |
| Dividend per share8 | 0,00 | 0,00 | 0,12 | 0,15 | 0,18 | 0,18 | 0,19 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: KPMG
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Schott Pharma | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A3ENQ5 | DE000A3ENQ51 | AG & Co. KGaA | 3.298,46 Mio € | 28.09.2023 | 9F2C268V+9J | |
| PE 2027e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 20,09 | 24,04 | 0,84 | 25,83 | 3,81 | 18,33 | 3,34 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 0,15 | 0,18 | 0,18 | 0,82% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 03.02.2026 | 11.02.2026 | 13.05.2026 | 12.08.2026 | 10.12.2026 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| +20,52% | +32,75% | +45,03% | -7,20% | -18,89% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
